Other

The United States of America as Represented by the Department of Health

Maryland Mental Health Institute, LLC

Finzi, Eric

Rosenthal, Norman E.

Norman E Rosenthal

Eric Finzi

Stephen B Leighton

Thomas A Wehr

Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.

Treatment of panic disorder using botulinum toxin

Methods are disclosed for treating post traumatic stress disorder (PTSD) in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.

Treatment of post-traumatic stress disorder using botulinum toxin A

Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin

Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.

Treatment of social anxiety disorder using botulinum toxin

A device for delivering high intensity light to a patient's eyes for treating seasonal affective disorder and the like uses a point source of light such as a high intensity halogen or other incandescent bulb, and directs a large fraction of the light from the bulb directly into the patient's eyes without focusing the light in such a way as to cause damage to the eye or discomfort to the patient. This is accomplished by the use of a positive lens which focuses the light from the high intensity bulb directly in front of the patient's eyes. The light appears to the patient to be coming from an area much larger than the actual point source, and hence is more comfortable for the patient. The patient is assured of receiving a significant dosage of light no matter which way he is directing his gaze.

Growing community of inventors

Rockville, MD, United States of America

Norman E Rosenthal